This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 92/1/111    most recent 01.RES.0000049100.22673.F6v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campos, A. H. Articles by Gibbons, G. H. Search for Related Content PubMed PubMed Citation Articles by Campos, A. H. Articles by Gibbons, G. H. Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Functional genomics

(Circulation Research. 2003;92:111.)
© 2003 American Heart Association, Inc.

Molecular Medicine

DNA Microarray Profiling to Identify Angiotensin-Responsive Genes in Vascular Smooth Muscle Cells

Potential Mediators of Vascular Disease

Alexandre H. Campos, Ying Zhao, Matthew J. Pollman, Gary H. Gibbons

From the Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, Ga.

Correspondence to Gary H. Gibbons, Cardiovascular Research Institute, Morehouse School of Medicine, 720 Westview Dr, SW, Research Wing, Room 245, Atlanta, GA 30310. E-mail ggibbons{at}msm.edu

Angiotensin II (Ang II) induces changes in vessel structure by its capacity to activate genes that are coupled to signaling pathways such as extracellular signal–regulated kinase (ERK), p38, and phosphatidylinositol 3-kinase (PI3K). Using a DNA microarray containing 5088 genes and expressed sequence tags, we initially established a database of replicated experiments (n=4) to define the variances in mRNA expression in response to Ang II versus vehicle treatment. We observed a wide range of values for the coefficients of variation in a gene-specific manner. Guided by power calculations, we used statistical inference on a sufficient number of experimental replicates to minimize the number of false-negatives and define a subset of Ang II–responsive genes (P<0.05). To further characterize the molecular circuitry that couples Ang II stimulation with mRNA expression, we assessed expression profiles in the presence and absence of inhibitors of ERK, p38, and PI3K. Using two different methods of computational cluster analysis, we identified a subset of six matricellular proteins (eg, osteopontin and plasminogen activator inhibitor-1) that are coordinately upregulated by Ang II via an ERK/p38-dependent pathway. In addition, these cluster analyses identified calpactins I and II as novel Ang II–responsive genes. Given that Ang II promotes vascular lesion formation, we examined whether this matricellular gene cluster was also coordinately regulated in vivo. Indeed, we demonstrate that both calpactin I and osteopontin are upregulated in response to vascular injury. Taken together, the combined use of DNA microarrays, statistical inference, and cluster analysis identified novel, coordinately regulated Ang II–responsive genes that may mediate vascular lesion formation.

Key Words: vascular smooth muscle cells • angiotensin II • DNA microarray • matricellular genes

This article has been cited by other articles:

				P. Rose, J. Bond, S. Tighe, M. J. Toth, T. L. Wellman, E. M. B. de Montiano, M. M. Lewinter, and K. M. Lounsbury Genes overexpressed in cerebral arteries following salt-induced hypertensive disease are regulated by angiotensin II, JunB, and CREB Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1075 - H1085. [Abstract] [Full Text] [PDF]

				E. F Nogueira, C. A Vargas, M. Otis, N. Gallo-Payet, W. B Bollag, and W. E Rainey Angiotensin-II acute regulation of rapid response genes in human, bovine, and rat adrenocortical cells J. Mol. Endocrinol., December 1, 2007; 39(6): 365 - 374. [Abstract] [Full Text] [PDF]

				R. A. Pulver-Kaste, C. A. Barlow, J. Bond, A. Watson, P. L. Penar, B. Tranmer, and K. M. Lounsbury Ca2+ source-dependent transcription of CRE-containing genes in vascular smooth muscle Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H97 - H105. [Abstract] [Full Text] [PDF]

				M. Costa, S. Barogi, N. D. Socci, D. Angeloni, M. Maffei, B. Baragatti, C. Chiellini, E. Grasso, and F. Coceani Gene expression in ductus arteriosus and aorta: comparison of birth and oxygen effects Physiol Genomics, April 13, 2006; 25(2): 250 - 262. [Abstract] [Full Text] [PDF]

				R. Pullmann Jr., M. Juhaszova, I. L. de Silanes, T. Kawai, K. Mazan-Mamczarz, M. K. Halushka, and M. Gorospe Enhanced Proliferation of Cultured Human Vascular Smooth Muscle Cells Linked to Increased Function of RNA-binding Protein HuR J. Biol. Chem., June 17, 2005; 280(24): 22819 - 22826. [Abstract] [Full Text] [PDF]

				N. Kaplan-Albuquerque, Y. E. Bogaert, V. Van Putten, M. C. Weiser-Evans, and R. A. Nemenoff Patterns of Gene Expression Differentially Regulated by Platelet-derived Growth Factor and Hypertrophic Stimuli in Vascular Smooth Muscle Cells: MARKERS FOR PHENOTYPIC MODULATION AND RESPONSE TO INJURY J. Biol. Chem., May 20, 2005; 280(20): 19966 - 19976. [Abstract] [Full Text] [PDF]

				B. C. Blaxall, J. M. Miano, and B. C. Berk Angiotensin II: A Devious Activator of Mineralocorticoid Receptor-Dependent Gene Expression Circ. Res., April 1, 2005; 96(6): 610 - 611. [Full Text] [PDF]

				A. D. Weisberg, F. Albornoz, J. P. Griffin, D. L. Crandall, H. Elokdah, A. B. Fogo, D. E. Vaughan, and N. J. Brown Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 365 - 371. [Abstract] [Full Text] [PDF]

				G. H. Gibbons, C. C. Liew, M. O. Goodarzi, J. I. Rotter, W. A. Hsueh, H. M. Siragy, R. Pratt, and V. J. Dzau Genetic Markers: Progress and Potential for Cardiovascular Disease Circulation, June 29, 2004; 109(25_suppl_1): IV-47 - IV-58. [Full Text] [PDF]

				F. Schwartz, A. Duka, E. Triantafyllidi, C. Johns, I. Duka, J. Cui, and H. Gavras Serial analysis of gene expression in mouse kidney following angiotensin II administration Physiol Genomics, December 16, 2003; 16(1): 90 - 98. [Abstract] [Full Text] [PDF]

				E. L. Schiffrin and R. M. Touyz Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade J. Am. Coll. Cardiol., September 3, 2003; 42(5): 911 - 913. [Full Text] [PDF]

				E. L. Schiffrin and R. M. Touyz Inflammation and Vascular Hypertrophy Induced by Angiotensin II: Role of NADPH Oxidase-Derived Reactive Oxygen Species Independently of Blood Pressure Elevation? Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 707 - 709. [Full Text] [PDF]

				M. B. Taubman Angiotensin II: A Vasoactive Hormone With Ever-Increasing Biological Roles Circ. Res., January 10, 2003; 92(1): 9 - 11. [Full Text] [PDF]